Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 May-Jun;46(5):546-52.
doi: 10.1016/j.jsat.2014.01.005. Epub 2014 Jan 17.

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

Adam Bisaga  1 , Maria A Sullivan  2 , Andrew Glass  2 , Kaitlyn Mishlen  2 , Kenneth M Carpenter  2 , John J Mariani  2 , Frances R Levin  2 , Edward V Nunes  2
Affiliations
Randomized Controlled Trial

A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence

Adam Bisaga et al. J Subst Abuse Treat. 2014 May-Jun.

Abstract

There is preclinical support for using NMDA receptor glutamatergic antagonists to aid in naltrexone-based treatment of opioid dependence. We hypothesized that adding memantine will improve efficacy of extended-release (XR) naltrexone to prevent relapse. In this double blind study opioid-dependent participants (N=82) underwent inpatient detoxification and naltrexone induction. During naltrexone initiation participants were randomized to receive memantine 40 mg or placebo and continued treatment for 12-weeks with XR naltrexone and relapse-prevention therapy. Sixty eight percent of participants completed detoxification and received the first dose of XR naltrexone. Rates of trial completion were significantly greater in participants receiving placebo than memantine (70% vs. 43%, p<0.05). Severity of opioid withdrawal symptoms during the first 3 weeks of the trial appeared to be lower in the group receiving memantine (p=0.07). Adding memantine does not appear to increase the effectiveness of injectable XR naltrexone as a relapse prevention strategy in opioid dependence and may lead to an increase in treatment drop-out.

Keywords: Memantine; NMDA receptors; Naltrexone; Opiate dependence; Pharmacotherapy trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort diagram summarizing participant flow
Figure 2
Figure 2
Kaplan-Meier curve of patient retention throughout the 12-week medication trial by treatment condition with 95% confidence limits.
Figure 3
Figure 3
Observed SOWS scores throughout the 12-week medication trial by treatment condition
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl) 2001;157(1):1–10. - PubMed
    1. Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 2011;119(1–2):e23–e29. - PMC - PubMed
    1. CASA Columbia, T. Addiction Medicine: Closing the Gap between Science and Practice. New York: The National Center on Addiction and Substance Abuse at Columbia University; 2012.
    1. CDC. CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10–13. - PubMed
    1. Comer SD, Sullivan MA. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl) 2007;193(2):235–245. - PubMed

Publication types

MeSH terms